{"id":840525,"date":"2025-04-23T08:10:25","date_gmt":"2025-04-23T12:10:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/"},"modified":"2025-04-23T08:10:25","modified_gmt":"2025-04-23T12:10:25","slug":"briacell-announces-four-clinical-data-presentations-at-asco-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/","title":{"rendered":"BriaCell Announces Four Clinical Data Presentations at ASCO 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, April  23, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 \u2013 June 3 at McCormick Place, Chicago, IL.<\/p>\n<p align=\"justify\">The details of the poster presentation sessions and publish-only abstract are listed below.<\/p>\n<p align=\"justify\">\n        <strong>Abstract Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician\u2019s choice in advanced metastatic breast cancer (BRIA-ABC) <\/strong><br \/>\n        <br \/>\n        <strong>Session Date and Time: 6\/2\/2025 9:00 AM-12:00 PM CDT<\/strong><br \/>\n        <br \/>\n        <strong>Abstract Number for Publication: <\/strong>TPS1138 <br \/><strong>Poster Board Number: <\/strong>108a<br \/><strong>Session Type and Title: <\/strong>Poster Session \u2013 Breast Cancer\u2014Metastatic<\/p>\n<p align=\"justify\">\n        <strong>Abstract Title: Bria-IMT + checkpoint inhibitor: Phase I\/II survival results compared to benchmark trials in metastatic breast cancer<\/strong><br \/>\n        <br \/>\n        <strong>Session Date and Time: 6\/2\/2025 9:00 AM-12:00 PM CDT<\/strong><br \/>\n        <br \/>\n        <strong>Abstract Number for Publication: <\/strong>1096<br \/><strong>Poster Board Number: <\/strong>75<br \/><strong>Session Type and Title: <\/strong>Poster Session \u2013 Breast Cancer\u2014Metastatic<\/p>\n<p align=\"justify\">\n        <strong>Abstract Title: Trial in progress: A study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer<\/strong><br \/>\n        <br \/>\n        <strong>Session Date and Time: 6\/2\/2025 9:00 AM-12:00 PM\u00a0CDT<\/strong><br \/>\n        <br \/>\n        <strong>Abstract Number for Publication: <\/strong>TPS1136<br \/><strong>Poster Board Number: <\/strong>107a<br \/><strong>Session Type and Title: <\/strong>Poster Session \u2013 Breast Cancer\u2014Metastatic<\/p>\n<p align=\"justify\">\n        <strong>Publish-Only Abstract Title<\/strong>: <strong>Impact of HLA Matching on Clinical Outcomes in a Phase 2 Trial of Bria-IMT\u2122 Plus Anti PD1 in Advanced Breast Cancer<\/strong><\/p>\n<p align=\"justify\">Abstracts will be released at 5:00 PM (ET) on Thursday, May 22, 2025.<\/p>\n<p align=\"justify\">Following the presentations, copies of the presentations will be posted on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OoODcvDbGeok0mXLgyDYn3vWUKCdLHkRdWTGZYCYyPwySAPHlU8WxQYkH7NkNjzwgOuStMtcIAw_ioZkDbrP6co759CM6oyfT9acvCNOYthXOyZ8_kI2gmhPHIHgZ4hydarTM3utXtE0j0E74IZrtCPaGeBeLBBDEk1JMYQPgzk=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/scientific-publications\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OoODcvDbGeok0mXLgyDYn3vWUKCdLHkRdWTGZYCYyPwVleuxns2rNXNtBx2cnSSPhMNam0dL-tsTPs-lWdbVSA_gJpyQ7z6rpI82jsvK4ds=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell presenting four clinical data presentations at the 2025 American Society of Clinical Oncology; and the contents of all such presentations are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jbaeg3F7LHc2Ucgr6N2XNXAknwCJp0hvg0wVdgek-stJbpoeK-MnqbKJ47oGlETLy5374Aywm6h0Sag2k1m1VJV_Gm8MwYbKKTidrYaGaTI=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/u><\/strong>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jbaeg3F7LHc2Ucgr6N2XNTJvSJZTH6ss_lzeKuZlp-4JhgP5-azo1Zt9hN1G-WX4cv8eHiZMdzX2TaAEMtjUrw==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bsasIkocH4IfZk5ID4olT0Se9bbeTbre7EXt5np_Y5BsJwMpNCeLswCzwKaPO7BBfHODu_6YWTFtUcjfHEib7LhHONVxy4gyj41eltGV-RU=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v9cUbSbbDmHF-nMmoTppaEM4j4o96v_wENuyvTiaOCqcEj15m6qNiORZDeGpkQxt2PaeNCPY7CdFegHBb3wn-R7Tk8fLl2aJbHl3NMPJXKw=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmNiNzBhZTgtMmIyYi00MmFkLTk1YWMtYjY2MjRkNWZiNmU3LTExMDIyMjktMjAyNS0wNC0yMy1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 \u2013 June 3 at McCormick Place, Chicago, IL. The details of the poster presentation sessions and publish-only abstract are listed below. Abstract Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician\u2019s choice in advanced metastatic breast cancer (BRIA-ABC) Session Date and Time: 6\/2\/2025 9:00 AM-12:00 PM CDT Abstract Number for Publication: TPS1138 Poster &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Announces Four Clinical Data Presentations at ASCO 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-840525","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 \u2013 June 3 at McCormick Place, Chicago, IL. The details of the poster presentation sessions and publish-only abstract are listed below. Abstract Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician\u2019s choice in advanced metastatic breast cancer (BRIA-ABC) Session Date and Time: 6\/2\/2025 9:00 AM-12:00 PM CDT Abstract Number for Publication: TPS1138 Poster &hellip; Continue reading &quot;BriaCell Announces Four Clinical Data Presentations at ASCO 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T12:10:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Announces Four Clinical Data Presentations at ASCO 2025\",\"datePublished\":\"2025-04-23T12:10:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/\",\"name\":\"BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=\",\"datePublished\":\"2025-04-23T12:10:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-four-clinical-data-presentations-at-asco-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Announces Four Clinical Data Presentations at ASCO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - Market Newsdesk","og_description":"PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 \u2013 June 3 at McCormick Place, Chicago, IL. The details of the poster presentation sessions and publish-only abstract are listed below. Abstract Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician\u2019s choice in advanced metastatic breast cancer (BRIA-ABC) Session Date and Time: 6\/2\/2025 9:00 AM-12:00 PM CDT Abstract Number for Publication: TPS1138 Poster &hellip; Continue reading \"BriaCell Announces Four Clinical Data Presentations at ASCO 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-23T12:10:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Announces Four Clinical Data Presentations at ASCO 2025","datePublished":"2025-04-23T12:10:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/","name":"BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=","datePublished":"2025-04-23T12:10:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzAyNSM2ODk5OTA3IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-four-clinical-data-presentations-at-asco-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Announces Four Clinical Data Presentations at ASCO 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/840525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=840525"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/840525\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=840525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=840525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=840525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}